Phase III
Magnitude Study
- Study HIC#:2000036310
- Last Updated:01/22/2026
This study is testing an investigational gene-editing treatment designed to reduce the production of transthyretin (TTR), a protein that causes amyloid buildup in the heart. Participants will receive a single intravenous infusion of either the study treatment or placebo and will be followed closely to assess safety and heart-related outcomes.
Contact Us
For more information about this study, including how to volunteer, contact:
Cinthia de Freitas
- Phone Number: 1-203-785-2776
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
- Adults aged 18–90 years
- Diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM)
